Molecular Medicine and Cancer Therapeutics Lab, Department of Zoology, Faculty of Sciences, University of Central Punjab, Lahore, Pakistan.
Applied Molecular Biology and Biomedicine Lab, Department of Zoology, University of Narowal, Narowal, Pakistan.
Mol Cell Biochem. 2024 Jan;479(1):1-11. doi: 10.1007/s11010-023-04707-1. Epub 2023 Mar 21.
Lipophagy is a selective degradation of lipids by a lysosomal-mediated pathway, and dysregulation of lipophagy is linked with the pathological hallmark of many liver diseases. Downregulation of lipophagy in liver cells results in abnormal accumulation of LDs (Lipid droplets) in hepatocytes which is a characteristic feature of several liver pathologies such as nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH). Contrarily, upregulation of lipophagy in activated hepatic stellate cells (HSCs) is associated with hepatic fibrosis and cirrhosis. Lipid metabolism reprogramming in violent cancer cells contributes to the progression of liver cancer. In this review, we have summarized the recent studies focusing on various components of the lipophagic machinery that can be modulated for their potential role as therapeutic agents against a wide range of liver diseases.
脂噬作用是溶酶体介导的脂质选择性降解途径,脂噬作用的失调与许多肝脏疾病的病理标志有关。肝细胞中脂噬作用的下调导致 LD(脂质滴)在肝细胞中的异常积累,这是几种肝脏疾病的特征,如非酒精性脂肪性肝病(NAFLD)和非酒精性脂肪性肝炎(NASH)。相反,激活的肝星状细胞(HSCs)中脂噬作用的上调与肝纤维化和肝硬化有关。恶性肿瘤细胞中的脂质代谢重编程有助于肝癌的进展。在这篇综述中,我们总结了最近的研究,这些研究集中在脂噬作用机制的各种成分上,这些成分可以被调节,以发挥其作为治疗剂的潜力,针对广泛的肝脏疾病。